Asia Pacific real estate investment news and information
IGIS Asia Investment Management, the Singapore-based investment arm of South Korea’s IGIS Asset Management, has teamed up with a leading Korean biopharmaceuticals group to launch a new platform for life science real estate investments across Asia Pacific.
The venture, which… Read More>>
Singaporean sovereign wealth fund GIC is expanding its biotech portfolio by teaming up with BlackRock Alternatives Real Estate and British Airways’ New Airways Pension Scheme (NAPS) to invest in a life sciences project in London’s King’s Cross district.
Developed by… Read More>>
The US real estate platform of Gemini Investments has made its first foray into the life sciences market by picking up a biotech-oriented office building in the San Francisco Bay area for about $59.4 million, at the same time that… Read More>>
Australia’s Elanor Funds Management has reportedly received help from Malaysian asset manager Permodalan Nasional Berhad to complete the A$289 million ($214 million) recapitalisation of the Elanor Healthcare Real Estate Fund.
The capital injection will provide a full liquidity event for… Read More>>
A joint venture between Dutch pension fund manager APG Asset Management and Singapore healthcare-focused private equity firm CBC Group has made its third investment within four months by picking up an industrial site in western Shanghai’s Qingpu district.
CBC Healthcare… Read More>>
Singapore-listed CapitaLand Ascendas REIT plans to convert one of its California office buildings into a life science property after fully leasing the asset to a US pharmaceutical company.
The trust formerly known as Ascendas REIT will equip the San Diego… Read More>>
A joint venture between Dutch pension fund manager APG Asset Management and Singapore healthcare-focused private equity firm CBC Group has acquired a pair of Beijing assets at a cost of over $180 million in the latest show of confidence in… Read More>>
ESR has acquired a business park in the Shanghai biotech cluster known as Zhangjiang Pharma Valley, marking the industrial specialist’s first-ever life sciences asset.
Hong Kong-listed ESR bought the two-building campus from mainland developer Yango for an undisclosed price earlier… Read More>>
Australian developer Lendlease has teamed up with Dutch pension fund and asset manager PGGM in a S$1 billion ($720 million) strategy that will invest in innovation and life science properties across Australia, Japan and Singapore, according to a joint announcement… Read More>>
Hong Kong’s Kailong Group is making preparations for a life sciences project on a Kowloon site acquired more than two years ago, with the real estate fund manager announcing a partnership with EC Healthcare to develop a medical building anchored… Read More>>
